produced in a human cell line with human-like post-translational protein processing and without chemical modification or fusion to any other protein. [13] [14] [15] [16] [17] Nuwiq ® is fully sulphated, which ensures a high affinity to circulating von Willebrand factor, contains only human glycans and is therefore devoid of potentially antigenic nonhuman epitopes present in rFVIII derived from hamster cell lines. 13, 15, 18, 19 In patients with haemophilia A, Nuwiq ® has been shown to be effective in the treatment and prevention of bleeds and in surgical prophylaxis in adults and children. [20] [21] [22] The efficacy and safety of Nuwiq ® in children with severe haemophilia A was demonstrated in a prospective phase III multinational clinical study (GENA-03) and reported previously in this journal. 21 In 56 paediatric previously treated patients (PTPs) who received prophylaxis for ≥50 exposure days (EDs) and at least 6 months, bleeding rates were low, and no FVIII inhibitors or treatment-related serious adverse events were reported. 21 The study presented here (GENA-13) was an extension of GENA-03 with the aim to assess the long-term tolerability, immunogenicity and efficacy of Nuwiq ® in these children.
| MATERIAL SANDME THODS

| Studydesign
GENA-13 was a prospective, open-label, uncontrolled, international multicentre phase IIIb, long-term extension of a previously described study in previously treated children aged 2-12 years (GENA-03). 21 All patients who completed GENA-03 according to protocol were eligible to enter GENA-13. Ten centres from the UK, Czech Republic, Poland, Russia, France and Romania participated in the extension study.
| Studypatientsandtreatment
Participating patients had completed the GENA-03 study by having a study participation period of at least 6 months and 50 EDs. 21 Nuwiq ® prophylaxis was continued without interruption at the same dose and dosing interval, either every other day or 3 times weekly. 21 Written informed consent was provided by the patients' parents (or legal guardians). The study was conducted in compliance with Good Clinical Practice, the Declaration of Helsinki, and national laws. Patients were categorized by age group (2-5 and 6-12 years) according to their age at baseline visit in the initial study (GENA-03).
| Outcomemeasures
The primary endpoints were the long-term tolerability and immunogenicity of Nuwiq ® . Inhibitor activity was assessed at screening, every 3 months thereafter and at the end of the study by the modified Bethesda assay (Nijmegen modification 23 ) as suggested by the European Medicines Agency. 24 At the same intervals, antirecombinant human FVIII antibodies were measured by enzyme-linked Ruthenium-fluorescent immunosorbent assay. In vivo recovery (IVR) was calculated at baseline and end of study from FVIII:C plasma concentrations measured prior to infusion and at 30 ± 5 minutes and 2 hours ± 5 minutes postinfusion. Secondary endpoints were the long-term efficacy of prophylactic treatment, efficacy in the treatment of bleeds and efficacy of surgical prophylaxis, as described previously. 21 Annualized bleeding rates (ABRs) were estimated based on a negative binomial counting regression model. Bleeding rates per year and estimated ABRs were calculated based on the time period on prophylaxis, excluding time periods for surgeries. The haemophilia joint health score (HJHS), a measure of joint health in those joints most commonly affected in haemophilia, was assessed at baseline, every 6 months thereafter and at the completion visit.
Prophylactic dosing data and estimated ABRs from GENA-03
were analysed for the 49 patients who continued into the extension study in order to compare these parameters over time.
| Statistics
Due to the explorative nature of the primary endpoint, no interferential analysis involving formal testing was conducted and the statistical analyses were descriptive.
| RE SULTS
| Patients
Of the 59 patients enrolled into GENA-03, 49 continued into the extension study. Eight patients from Turkey did not enter the extension study due to a delay in regulatory approval of the study and 2 patients did not enter the extension as they discontinued the main study prematurely. Sixteen patients underwent at least 1 surgery, of which 14 were treated with Nuwiq ® for surgical prophylaxis ( Figure 1 ). The patients' demographic characteristics at entry into the extension study are shown in Table 1 .
| Extentofexposure
The median (range) study period was 30. 
| Bleedingtypeandseverity
During the course of the study, there were 336 bleeds in 41 patients.
Of these, 81 (24.1%) were spontaneous, 209 (62.2%) were traumatic, 2 (0.6%) were postoperative and 14 (4.2%) and 30 (8.9%) were classified as other and not documented, respectively. Of all bleeds, 182 (54.2%) were minor, 146 (43.5%) were moderate to major and 5 (1.5%) were major to life-threatening; the severity of 3 (0.9%) bleeds was not documented. All 5 major to life-threatening bleeds occurred in older children. Four of these were traumatic bleeds, all of which occurred in 1 patient and one was a spontaneous bleed in another patient (haematuria requiring hospitalization). The severity of the 4 traumatic bleeds was rated by the patient and/or his parents in the study diary, and the patient's physician commented that none of the 4 traumatic bleeds would objectively qualify as major to life-threatening.
The most common sites of spontaneous bleeds were the nose, the knee and the leg (18.5% each). Knee (16.7%) and leg (12.4%) were also the most common sites of traumatic bleeds. Of the 336 bleeds, 101 (30.1%) occurred in joints.
| Bleedingrates
The bleeding rates per year and estimated ABRs for spontaneous, joint and all bleeds by age group are shown in Table 2 . Younger children presented with a lower ABR for spontaneous bleeds and for all bleeds compared with older children. 
| Treatmentofbreakthroughbleeds
Of the 336 bleeds that occurred during the study, 25 (7.4%) were not The efficacy assessment according to bleed severity is presented in Table 3 . Overall, 83.0% of treated and evaluated bleeds (N = 305)
were treated successfully ("excellent" or "good" efficacy rating). The treatment success rate was higher in younger children than in older children across all severities. Of 96 treated and rated joint bleeds, efficacy was "excellent" or "good" for 80 (83.3%) bleeds, "moderate" for 15 (15.6%) bleeds and "none" for 1 (1.0%) bleed. , that is an efficacy assessment of "excellent" or "good," was achieved for all 17 rated surgeries based on assessments by both the surgeon and the haematologist (Table 4) .
| Surgicalprophylaxis
performed, and 4 minor and 7 major surgeries were performed in older children. Across the 24 surgeries, a mean (SD) of 10.8 (8.4)
| Haemophiliajointhealthscore
At the start of the long-term extension study patients presented 
| Invivorecovery
In vivo recovery values were not markedly different at study start compared with study completion for both age groups (Table 5 ). In the overall population, mean IVR (% per IU/kg) at the start of the extension study according to the chromogenic assay was 1.78 compared with 1.71 at study completion.
| Safety
Patients experienced a total of 317 treatment-emergent adverse events, of which 144 occurred in younger children and 173 in older children. Two treatment-emergent adverse events were classified as possibly or probably related to Nuwiq ® : one patient aged 5 at study start experienced dyspnoea of mild severity. Another patient aged 3 at study start developed fever, which was classified as serious as it required prolonged hospitalization. The event was resolved without sequelae. One patient aged 12 died during the study because of multiple-organ failure following a car accident. No relevant patient history and co-existing illness were recorded, and the event was classified as not related to the study drug. No patients withdrew as a consequence of a drug-related adverse event.
| Immunogenicity
No patient developed FVIII inhibitors. One patient tested positive for noninhibitory FVIII antibodies at the 18-month visit and 2 subsequent visits (including the study completion visit). The prophylactic efficacy in this patient was excellent, with no bleeds during the study.
| D ISCUSS I ON
This was a long-term extension study of the multinational phase III study enrolling previously treated paediatric patients with severe F I G U R E 2 Estimated annualized bleeding rates in main study and its long-term extension. A, all children (2-12 y); B, younger children (2-5 y); C, older children (6-12 y). Only patients enrolled in both studies were considered. Annualized bleeding rates were estimated based on calculations using a negative binomial counting regression model and taking into account only the time under prophylaxis. ABR, annualized bleeding rate; BE, bleeding episode; CI, confidence interval; LTE, long-term extension haemophilia A. 21 The long-term tolerability, immunogenicity and efficacy of Nuwiq ® were investigated, and patients were treated on average for approximately 2.5 years. Patients had estimated ABRs of 0.67 and 2.88 for spontaneous bleeds and all bleeds, respectively.
Annualized bleeding rates were lower in younger children than in older children, which was partially driven by higher incidence of traumatic bleeds, consistent with previously published data. 21, 25 In the predecessor study, the ABRs for all bleeds were 2.47 for younger, 4.74 for older children and 3.54 for both age groups for the patients who continued to the extension study. In particular, the ABR for spontaneous bleeds in younger children decreased in the extension study compared with the main study (71% reduction). Overall, patients in the extension study continued to receive a similar dose per infusion as in the main study. 21 The percentage of bleeds requiring 1 or 2 infusions was comparable between the main study and the extension study in the whole population (81.3% vs 84.9%, respectively). 21 The efficacy of treatment of breakthrough bleeds was comparable between the main study and the extension study in the whole population (82.4% and 83.0% "excellent" or "good" for all breakthrough bleeds, respectively). While the efficacy ratings remained stable in older children (82.7% vs 80.0% "excellent" or "good"), they improved in younger children during the extension study (81.8% vs 92.9% "excellent" or "good," respectively). 21 Overall, the percentage of bleeds treated with "excellent" or "good" efficacy was higher for minor bleeds than moderate to major bleeds in the extension study (92.0% vs 72.3%, respectively) and in the main study (98.4% vs 60.9%, respectively). 21 Only 6 of the 305 (2%) treated and rated bleeds in the extension study had an efficacy rating of "none" and all were moderate to major bleeds in children aged 6-12 years (6/137, 4.4%).
Twenty-four surgeries were performed in 14 patients during the course of the long-term extension, 12 (50%) of which (performed in 8 patients) were major. Both the surgeon and the haematologist rated the surgical prophylaxis as "excellent" for all 17 procedures (10 major) with documented efficacy assessments. During the main study, overall efficacy was rated as "excellent" by the surgeon and the haematologist for all 5 evaluated procedures. 21 One study with the previous generation rFVIII Advate ® in paediatric patients aged 3.1 (1.5) years reported haemostatic efficacy as "excellent" or "good" in 3 out of 5 evaluable surgeries. 26 In a recent study on rFVIIIFc (Eloctate ® ) in paediatric patients aged 1-11 years, 7 minor surgeries were performed in 7 patients and the haemostatic efficacy of these surgeries was rated as "excellent" (5 surgeries) or "good" (2 surgeries). 27 Overall, the haemostatic efficacy during surgery in this extension study is in line with published data for Nuwiq ® and other FVIII products. 26, 27 With 24 procedures, this extension study provides one of the largest surgery data pools in paediatric haemophilia A patients treated with FVIII. The severity of bleeds was rated by the patients and/or their parents in the study diaries, and the patient's physician commented that none of these 4 traumatic bleeds would objectively qualify as major to life-threatening bleeds, which is supported by the fact that each bleed required only 1 infusion to resolve. c Haematuria that required hospitalization, 6 injections were given over 5 d.
n, number of breakthrough bleeds; N, number of patients with breakthrough bleeds.
TA B L E 3 Efficacy assessment for the treatment of breakthrough bleeds during standard prophylaxis
Prolonged bleeding into joints might ultimately cause joint destruction. Guidelines recommend the incorporation of a standardized clinical examination score into the prospective assessment of patients receiving prophylaxis, such as the HJHS. 28 The HJHS is a frequently utilized tool that is also validated in children. 29 In the extension study, children presented with well-preserved joint function according to HJHS that was not impaired over the course of the study. Surgeries were prospectively defined as major if any of the following criteria were met: requiring general or spinal anaesthesia; requiring opening into the great body cavities; in the course of which hazards of severe haemorrhage was possible; requiring haemostatic therapy for at least 6 d; orthopaedic interventions involving joints (ankle, knee, hip, wrist, elbow, shoulder); 3rd molar extraction or extraction of 3 or more teeth; or surgeries/conditions in which the patient's life was at stake. All other surgeries were classified as minor. a Evaluated and documented surgeries performed under Nuwiq ® treatment rated as excellent or good. b Minor surgery in younger children: port catheter insertion/removal (3), dental surgery (2), bladder surgery (1), cutting of tongue frenulum (1), inguinal hernia (1). Overall efficacy evaluation of the haematologist was not available for 3 procedures (dental [2] , cutting of tongue frenulum [1] ); overall efficacy evaluation of the surgeon was not available for 5 procedures (port catheter insertion [2] , dental [2] , cutting of tongue frenulum [1] ). c Minor surgery in older children: dental (2), removal of osteoma in left auditory duct (1), suppurative appendicitis (1). d Major surgery in younger children: port catheter insertion/removal (3), dental surgery (2) . Overall efficacy evaluation of the surgeon was not available for 2 procedures (port catheter insertions). e Major surgery in older children: port catheter insertion/removal (4), dental (1), ingrown toenail (1), evacuation haemarthrosis of the left knee (1).
TA B L E 4 Surgical procedures by surgical severity and age group
TA B L E 5
In vivo recovery (% per IU/kg) at baseline and end of study The IVR values at the start and end of the extension study were not markedly different. Mean results from the one stage assay were lower compared with the chromogenic assay, a well-documented difference described in the literature. 20, 21, [30] [31] [32] [33] In vivo recovery values were lower in younger children across both assays compared with older children, which is consistent with published data. 21, 34 In vivo recovery values observed during the course of the extension were in line with those reported for all 59 patients at the start of the main study. 21 The safety of Nuwiq ® was assessed over a mean of almost 30 months with 27 507 115 IU administered over the course of the study in all patients receiving the study drug. Two adverse events
were assessed as treatment-related: dyspnoea in 1 patient; and fever which was rated as serious because it required prolonged hospitalization in another. No patient discontinued the study due to a drug-related adverse event. Importantly, during both the main and extension studies, no inhibitors developed despite more than 50% of patients having high-risk F8 gene mutations. 35, 36 This study has some limitations. Due to the design inherent to long-term extensions, there is no control group. Long-term extensions might also preferentially retain patients responding well to therapy, thus biasing the observed outcomes. However, in the main study, only 1 patient withdrew due to insufficient therapeutic response. All patients not continuing into the extension were recruited in 1 country (Turkey) and were not enrolled into GENA-13 for administrative reasons unrelated to the efficacy and safety of the study drug.
21
The long-term prophylactic use of Nuwiq ® led to low bleeding rates with no inhibitor development and with a favourable safety profile. A decrease in spontaneous estimated ABRs was observed compared with that in the original study with the same amount of FVIII used. These results indicate that Nuwiq ® is effective for the long-term prevention and treatment of bleeds in previously treated paediatric patients with severe haemophilia A. 
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